PURPOSE: Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival. PATIENTS AND METHODS: From 1990 to 2004, 75 patients were managed for LR of GCT at our institution. Clinical and pathologic parameters were reviewed. Estimates of cancer-specific survival were generated using the Kaplan-Meier method, and a Cox proportional hazards model was used to assess potential predictors of outcome. RESULTS: The median time to LR was 6.9 years (range, 2.1 to 37.7 years). Overall, 56 patients (75%) had LR in the retroperitoneum, including 25 (93%) of 27 patients initially managed without retroperitoneal lymph node dissection. The 5-year cancer-specific survival (CSS) was 60% (95% CI, 46% to 71%). Patients who underwent complete surgical resection at time of LR (n = 45) had a 5-year CSS of 79% versus 36% for patients without complete resection (n = 30; P < .0001). The 5-year CSS for chemotherapy-naive patients was significantly greater than patients with a prior history of chemotherapy as part of their initial management (5-year CSS, 93% v 49%, respectively). In multivariable analysis of pretreatment parameters available at the time of LR, the presence of symptoms (hazard ratio [HR] = 4.9) and multifocal disease (HR = 3.0) were associated with an inferior CSS. CONCLUSION: The data suggest that meticulous control of the retroperitoneum is critical to prevent LR in the retroperitoneum. In multivariable analysis, patients with a symptomatic presentation and those with multifocal disease have a significantly decreased survival. Survival is greatly improved if complete surgical excision of disease is attained.
PURPOSE: Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival. PATIENTS AND METHODS: From 1990 to 2004, 75 patients were managed for LR of GCT at our institution. Clinical and pathologic parameters were reviewed. Estimates of cancer-specific survival were generated using the Kaplan-Meier method, and a Cox proportional hazards model was used to assess potential predictors of outcome. RESULTS: The median time to LR was 6.9 years (range, 2.1 to 37.7 years). Overall, 56 patients (75%) had LR in the retroperitoneum, including 25 (93%) of 27 patients initially managed without retroperitoneal lymph node dissection. The 5-year cancer-specific survival (CSS) was 60% (95% CI, 46% to 71%). Patients who underwent complete surgical resection at time of LR (n = 45) had a 5-year CSS of 79% versus 36% for patients without complete resection (n = 30; P < .0001). The 5-year CSS for chemotherapy-naive patients was significantly greater than patients with a prior history of chemotherapy as part of their initial management (5-year CSS, 93% v 49%, respectively). In multivariable analysis of pretreatment parameters available at the time of LR, the presence of symptoms (hazard ratio [HR] = 4.9) and multifocal disease (HR = 3.0) were associated with an inferior CSS. CONCLUSION: The data suggest that meticulous control of the retroperitoneum is critical to prevent LR in the retroperitoneum. In multivariable analysis, patients with a symptomatic presentation and those with multifocal disease have a significantly decreased survival. Survival is greatly improved if complete surgical excision of disease is attained.
Authors: Martijn F Lutke Holzik; Harald J Hoekstra; Nanno H Mulder; Albert J H Suurmeijer; Dirk Th Sleijfer; Jourik A Gietema Journal: Ann Surg Oncol Date: 2003-03 Impact factor: 5.344
Authors: G Varuni Kondagunta; Jennifer Bacik; Alessia Donadio; Dean Bajorin; Stephanie Marion; Joel Sheinfeld; George J Bosl; Robert J Motzer Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Mehdi Shahidi; Andrew R Norman; David P Dearnaley; Judy Nicholls; Alan Horwich; Robert A Huddart Journal: Cancer Date: 2002-08-01 Impact factor: 6.860
Authors: Brett S Carver; Bobby Shayegan; Scott Eggener; Jason Stasi; Robert J Motzer; George J Bosl; Joel Sheinfeld Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: David W George; Richard S Foster; Robert A Hromas; Kent A Robertson; Gail H Vance; Thomas M Ulbright; Troy A Gobbett; Devan J Heiber; Nyla A Heerema; Heather C Ramsey; Virginia C Thurston; Sin-Ho Jung; Jianzhao Shen; David E Finch; Mark R Kelley; Lawrence H Einhorn Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544